Viking Therapeutics’ positive results for oral weight-loss drug has analysts backing buy ratings

Data from a Phase 1 trial is the latest bullish news from the biotech that may offer cheap entry to weight-loss mania.

Previous post Momentum stocks are outperforming S&P 500 by widest margin since 2008. Investors should be concerned.
Next post Tether integrates native USDT on Celo mainnet